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S100β as a serum marker in endocrine
resistant breast cancer
Sara Charmsaz1†, Éamon Hughes1†, Fiona T. Bane1, Paul Tibbitts2, Marie McIlroy1, Christopher Byrne1, Sinéad Cocchiglia1,
Jean McBryan1, Bryan T. Hennessy3, Róisín M. Dwyer4, Michael J. Kerin4, Arnold D. Hill2 and Leonie S. Young1*
Abstract
Background: Endocrine therapy is standard treatment for estrogen receptor (ER)-positive breast cancer. However,
its efficacy is limited by intrinsic and acquired resistance. Here the potential of S100β as a biomarker and inhibition
of its signaling network as a therapeutic strategy in endocrine treated patients was investigated.
Methods: The expression of S100β in tissue and serum was assessed by immunohistochemistry and an enzyme-
linked immunosorbent assay, respectively. The S100β signaling network was investigated in cell line models of
endocrine resistance by western blot, PCR, immunoprecipitation, and chromatin-immunoprecipitation. Endocrine
resistant xenografts and tumor explants from patients with resistant tumors were treated with endocrine therapy in
the presence and absence of the p-Src kinase inhibitor, dasatinib.
Results: Tissue and serum levels of S100β were found to predict poor disease-free survival in endocrine-treated patients
(n= 509, HR 2.32, 95% CI is 1.58–3.40, p< 0.0001 and n= 187, HR 4.009, 95% CI is 1.66–9.68, p= 0.002, respectively).
Moreover, elevated levels of serum S100β detected during routine surveillance over the patient treatment period
significantly associated with subsequent clinically confirmed disease recurrence (p= 0.019). In vivo studies demonstrated
that endocrine treatment induced transcriptional regulation of S100β which was successfully disrupted with tyrosine kinase
inhibition. In endocrine resistant xenografts and tumor explants from patients with endocrine resistant breast cancer,
combined endocrine and dasatinib treatment reduced tumor proliferation and down-regulated S100β protein expression
in comparison to endocrine treatment alone.
Conclusions: S100β has potential as a new surveillance tool for patients with ER-positive breast cancer to monitor ongoing
response to endocrine therapy. Moreover, endocrine resistant breast cancer patients with elevated S100β may benefit from
combined endocrine and tyrosine-kinase inhibitor treatment.
Trial registration: ClinicalTrials.gov, NCT01840293). Registered on 23 April 2013. Retrospectively registered.
Keywords: Biomarker, Endocrine resistance, Breast cancer, S100β, Estrogen receptor
Background
Endocrine therapies, both tamoxifen and aromatase inhibi-
tors (AIs), successfully treat ER-positive breast cancer. A
small but significant number of patients, however, will ac-
quire resistance and develop disease recurrence [1]. Clinic-
ally, undetected resistant tumors continue to be exposed to
adjuvant endocrine therapy, which can contribute to tumor
progression and development of metastatic disease [1].
Despite concentrated efforts to discover robust biomarkers
of endocrine sensitivity, no clinical assay to monitor real-
time patient response to endocrine treatment has been de-
veloped. Understanding tumor adaptation to endocrine
therapy has the potential to uncover new biomarkers of
drug sensitivity and novel therapeutic targets to detect and
treat endocrine resistant metastatic disease [2].
At a cellular level, increased tumor plasticity occurs in endo-
crine resistant breast cancer compared to sensitive tumors.
Studies from our group and others suggest that enhanced
tyrosine kinase signaling, re-expression of homeobox (HOX)
developmental proteins along with activation of steroid recep-
tor co-activator-1 (SRC-1) proteins cooperate to regulate
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breast cancer tumor adaptability [3–5]. HOXC11 and SRC-1
transcriptionally regulate the calcium-binding protein S100β,
and overexpression of SRC-1 together with HOXC11 results
in increased expression of S100β [3, 4, 6]. S100β is a member
of the S100 family of calcium-binding proteins, several of
which, including S100A7 and a truncated form of S100P, have
been associated with progressive breast cancer [7–9]. S100β is
detected at low levels in human serum; however, elevated
levels of serum S100β have been reported following injuries to
the central nervous system and in different types of tumors in-
cluding melanoma and breast cancer [3, 10–12].
Endocrine resistance is marked by a shift from steroid-
dependent to tyrosine kinase-dependent signaling [13]. Src is
a non-receptor tyrosine kinase which has roles in tumor pro-
gression, epithelial-to-mesenchymal transition, angiogenesis,
and the development of metastasis [14]. Interaction of SRC-
1 and Src kinase has been described in endometrial cancer,
suggesting the possibility of targeting SRC-1/HOXC11 inter-
action through inhibition of Src kinase activity [15]. Clinic-
ally, one of the most widely used Src kinase inhibitors is
dasatinib, which is a small molecule inhibitor that targets
kinase proteins including Src, BCR-ABL, cKit, and PDGFRβ
[16]. Results from clinical trials evaluating dasatinib in pa-
tients with advanced breast cancer demonstrated efficacy in
a subset of patients and suggests that patient stratification
would significantly enhance the benefit of Src kinase inhib-
ition [17, 18]. However, to date no gene signature has defined
tumors clinically sensitive to dasatinib as a single agent [19].
Here we examine the prognostic potential of serum S100β
as a monitoring tool for tumor response in patients with
breast cancer on endocrine treatment. We investigate the
mechanism of S100β production in endocrine resistant breast
cancer and demonstrate that inhibition of the Src kinase
pathway with the kinase inhibitor dasatinib can reduce tumor
progression in vivo.
Methods
Ethics
All clinical materials and, where relevant, informed consent
were collected following ethical approval from Beaumont
Hospital Medical Research Ethics Committee, St. Vincent’s
University Hospital Medical Research Ethics Committee,
and Galway University Hospital Clinical Research Ethics
Committee. This study was designed in accordance with the
guidelines concerning tumor marker studies [20].
All mouse experiments were performed in accordance
with the European Communities Council Directive (86/609/
EEC) and were reviewed and approved by Research Ethics
Committee under license from the Department of Health.
Patients and study design
For prognostic tissue studies, formalin-fixed, paraffin-
embedded (FFPE) breast tumor samples (n = 1079) were
obtained from archival cases at St. Vincent’s University
Hospital and Beaumont Hospital, Dublin, Ireland from
1987–1999 and from 2004–2008, respectively.
For prognostic serum studies, blood samples were col-
lected from patients with breast cancer attending the Na-
tional University Hospital Galway and Beaumont Hospital
from 1993–2006 and 2008–2014, respectively, prior to initial
surgery for the resection of primary breast tumor (n = 346).
For monitoring serum studies, pre-operative and serial
post-operative samples were collected from breast can-
cer patients enrolled in a dual-center Cancer Trials
Ireland-led trial (ICORG 09/07;NCT01840293/(Clinical-
Trials.gov)) from 2008–2014 (n = 181).
Included in this study were ER-positive patients who re-
ceived tamoxifen and/or AI (n= 625, tissue and n= 235,
serum) for 5 years, which was discontinued only in those
who suffered a relapse. Excluded from the analysis were pa-
tients who did not have breast surgery, those who had neoad-
juvant endocrine therapy, those on clinical trial or whose
specimens were irretrievable, patients with unknown S100β
status, or those with incomplete clinical data. Data on patients
included pathological characteristics (tumor size, grade,
lymph node status, ER/PR status) as well as treatment with
radiotherapy/chemotherapy. Detailed follow-up data (median
6.4 years for tissue and 5.5 years for serum studies) were col-
lected. The primary endpoint in this study was breast-specific
disease-free survival. A flow diagram with patient inclusion
and exclusion criteria for this study is presented in Fig. 1.
Specimens
Breast cancer tissue samples were formalin-fixed and paraffin
embedded (FFPE) and a tissue microarray (TMA) was con-
structed as previously described [21]. Serum samples were col-
lected from age-matched healthy volunteers (n=10, median
age 63.3 years). Serum was prepared by centrifugation (400 g
for 10 min) and stored within 3 h of collection at –80 °C.
Breast cancer ex vivo studies were carried out using fresh
tumor samples. Samples were cultured on gelatin sponges
(Spongostan, Johnson & Johnson Medical, Gargrave, UK) in
Minimum Essential Medium (MEM)/10% fetal calf serum,
L‐glutamine, 10–6 M letrozole with or without 1 μM dasati-
nib [22] and incubated for 5 days. Tumors were formalin-
fixed and embedded.
Assessment of tissue S100β
TMAs were immunostained using monoclonal mouse anti-
S100β antibody (AB-14849, Abcam, Cambridge, UK) specific
for S100β alpha-beta heterodimer and beta-beta homodimer.
TMAs were scored using the Allred system as previously de-
scribed [23]. A score of ≥3 was defined as positive. Two in-
dependent observers, without knowledge of prognostic
factors, scored the slides. The kappa score for the agreement
between the two independent reviewers was 0.935.
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Clinical assay for serum S100β
Serum S100β levels were determined using a commercial
enzyme-linked immunosorbent assay (ELISA) kit (364701,
Diasorin, Stillwater, MN, USA) according to the manufac-
turer’s instructions. The precision of the assay is >85%,
and the detection limit is 0.03 μg/L.
S100β cut-off levels were determined in a training set
comprising ten breast cancer patients with no relapse, ten
patients who went on to have confirmed disease recurrence,
and ten aged matched healthy controls. The upper limit of
normal was calculated (mean + (t0.975,n-1 x √(n+1/n) x SD)),
and 0.13 μg/L was taken as the cut-off (Additional file 1:
Figure S1); outliers were calculated as √0.13 μg/L. A valid-
ation study was carried out in 76 patients with breast cancer
and 59 ER-positive breast cancer patients; S100β serum sta-
tus was analyzed in relation to patient pathologic character-
istics and disease recurrence (Additional file 2: Table S1).
Cell studies
The endocrine sensitive cell line (MCF-7) was obtained
from the American Type Culture Collection (ATCC), and
the endocrine resistant cell line (LY2) was a gift from Rob-
ert Clarke (Georgetown University, Washington, DC,
USA) [24]. Cells were maintained as previously described
[25]. AI resistant LetR cells and AI sensitive ARO cells
were created as described previously [3]. Cell lines were
tested (Source Biosciences, Life Biosciences, Nottingham,
UK) for authenticity in accordance with ATCC guidelines.
Xenograft studies
Mouse experiments were performed as previously de-
scribed [26]. Endocrine sensitive (MCF-7) and endocrine
resistant (LY2) xenograft models were established. Mice
were supplemented with estrogen (0.25 mg/pellet, 60-
day release) and treated with tamoxifen (5 mg/pellet, 60-
day release; Innovative Research of America, Sarasota,
FL, USA) and dasatinib (50 mg/kg/day, oral gavage;
Bristol-Myers Squibb, New York, NY, USA) as indicated.
Tumor growth was recorded twice weekly by caliper
measurements, and tumors were imaged using an IVIS
whole body imaging system (Xenogen Corp, Alameda,
CA, USA) to detect luciferase activity of the LY2-luc
cells. Metastasis was detected by shielding the primary
tumor, and quantitative measurements of metastatic de-
posits were calculated using Living Image analysis software
(Xenogen). Formation of metastasis to the organs was also
confirmed by immunohistochemical analysis of the lung,
liver, and bone. Blood was collected at 2-week intervals by
facial vein bleeding to monitor S100β levels in serum.
Fig. 1 Flow chart of patients with breast cancer recruited to the clinical studies. For prognostic tissue studies, FFPE breast tumor samples (n = 1079)
were obtained from archival cases at St. Vincent’s University Hospital and Beaumont Hospital, Dublin, Ireland from 1987–1999 and from 2004–2008,
respectively. For prognostic serum studies, blood samples were collected from breast cancer patients attending the National University Hospital
Galway and Beaumont Hospital from 1993–2006 and 2008–2014, respectively, prior to initial surgery for the resection of primary breast tumor
(n = 346). For monitoring serum studies, pre-operative and serial post-operative samples were collected from patients with breast cancer enrolled
in a multicenter Cancer Trials Ireland-led trial (ICORG 09/07;NCT01840293/(ClinicalTrials.gov)) from 2008–2014 (n = 181)
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Chromatin immunoprecipitation
LY2 cells were treated with tamoxifen or tamoxifen and
dasatinib. Chromatin immunoprecipitation (ChIP) was
performed as previously described [23] using mouse anti-
HOXC11 6 μg ((15-288-22000 F, Genway Biotech, San
Diego, CA, USA)) and mouse anti-SRC-1 12 μg (F10,
Santa Cruz Biotechnology, Dallas, TX, USA). S100β
promoter-specific primers were used to amplify the DNA
forward: TGGCAGAGGAGAGAAGCTC and reverse:
TTCCTGAGCGTCCTCTTGG.
Western blot
Protein was harvested from breast cancer cells, electropho-
resed and immunoblotted with mouse anti-S100β (AB-14849,
Abcam, 1 in 250), anti-ERα (sc-8002, Santa Cruz Biotechnol-
ogy, 1 in 1000), anti-PR (sc-538, Santa Cruz Biotechnology, 1
Table 1 Associations of S100β expression in ER-positive endocrine-treated breast cancer tissue (n = 536) and serum (n = 187) with
clinicopathologic variables and disease recurrence using Fisher’s exact test. Associations between disease-free survival times and
individual variables using Wilcoxon. Median age for patient TMA and serum samples was 56.12 and 51.15 years respectively, and me-
dian follow-up time was 76.84 and 66.1 months respectively
Patient TMA Patient serum samples
Variable Total n S100β + ve S100β –ve p Fisher p Wilcoxon Total n S100β
≥0.13 μg/L
S100β
<0.13 μg/L
p Fisher p Wilcoxon
S100β 536 34.7% 65.30% <0.0001 187 10.16% 89.84% 0.0011
Age
≥55 303 56.45% 56.57% 1.0 0.4 75 47.37% 39.29% 0.622 0.4
<55 233 43.55% 43.43% 112 52.63% 60.71%
PR
+ ve 321 65.50% 66.56% 0.841 0.4 159 57.89% 88.62% 0.002 0.8
− ve 164 34.50% 33.44% 27 42.11% 11.38%
HER2
+ ve 85 18.93% 17.10% 0.619 0.2 26 15.79% 13.69% 0.732 0.7
− ve 394 81.07% 82.90% 161 84.21% 86.31%
Nodal status
+ ve 273 49.46% 52.62% 0.524 <0.0001 99 53.33% 58.71% 0.786 0.05
− ve 257 50.54% 47.38% 71 46.67% 41.29%
Grade
≥ Grade 3 147 34.88% 27.10% 0.079 0.03 52 31.58% 27.38% 0.788 0.2
< Grade 3 346 65.12% 72.90% 135 68.42% 72.62%
Tumor size
≥20 mm 369 70.97% 67.71% 0.493 0.004 137 94.44% 86.33% 0.473 0.5
<20 mm 167 29.03% 32.29% 20 5.56% 13.67%
Hormonal therapy
Tamoxifen 459 83.87% 86.57% 0.438 0.4 110 42.11% 60.71% 0.143 0.7
AI 126 25.81% 22.29% 0.392 0.5 108 73.68% 55.95% 0.152 0.2
Other therapy
Chemotherapy 166 34.64% 31.23% 0.431 0.1 119 61.11% 66.26% 0.794 0.2
Radiation 296 62.16% 52.01% 0.028 0.5 121 70.59% 74.66% 0.771 0.01
Herceptin 23 6.49% 3.14% 0.077 0.06 10 5.26% 5.36% 1.00 0.87
Recurrence
+ ve 156 40.32% 23.14% <0.0001 33 47.37% 14.29% 0.002
− ve 380 59.68% 76.86% 154 52.63% 85.71%
HOXC11
+ ve 74 83.93% 18.49% <0.0001 <0.0001
− ve 128 16.07% 81.51%
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in 1000), anti-p-Src 416 (2101S, Cell Signaling Technology,
Danvers, MA, USA, 1 in 1000), anti-c-Src (2109S, Cell Signal-
ing, 1 in 1000), anti-SRC-1 (sc-8995, Santa Cruz Biotechnol-
ogy, 1 in 150), anti-HOXC11 (15-288-22000 F, Genway
Biotech, 1 in 1000), and anti-β-actin (A1978, Sigma Aldrich,
St. Louis, MO, USA, 1 in 7500) as described previously [25].
Statistical analysis
Statistical analysis was performed using Prism (Graph-
Pad, San Diego, CA, USA) and Stata software (Stata-
Corp, College Station, TX, USA). Stata software was
used to perform receiver operating characteristic (ROC)
analyses. A 95% confidence interval (CI) was used to de-
termine significance. Survival times between groups
were compared using the Wilcoxon test adjusted for
censored values. Multivariate analysis for S100β was car-
ried out using Cox proportional hazards, modeled with
node, grade, and HER2 status using the Breslow method
for ties. Fisher’s exact test for two by two tables was used
for comparison of categorical data. A two-sided Stu-
dent’s t test was used for continuous variables. Values of
p ≤ 0.05 were considered significant.
Results
Elevated levels of S100β associate with poor disease-free
survival in patients with endocrine-treated breast cancer
The flow of the patients selected for the study is presented
in Fig. 1. In FFPE tissue from adjuvant endocrine-
treated patients expression of S100β strongly associated
with incidence of recurrence (n = 536, p < 0.0001) (see
Table 1) and poor disease-free survival time (n = 509, HR
2.32, 95% CI is 1.58–3.40, p < 0.0001, Cox proportional
hazard model) (Fig. 2a). No association was observed be-
tween S100β and classic clinicopathological variables;
however, as expected there was a strong association be-
tween S100β and HOXC11 expression (Table 1). As the
possibility of assessing S100β levels in patient serum
substantially enhances its clinical utility, a clinical
assay suitable for use in patients with breast cancer
was therefore developed. An appropriate cut-off of
S100β serum levels in patients (0.13 μg/L) was estab-
lished in a training set (Additional file 1: Figure S1) and
verified in a validation study (n = 76, all breast cancer
patients; n = 59, ER-positive breast cancer patients)
(Additional file 2: Table S1). In our test endocrine-
treated patient population, pre-operative elevated S100β
Fig. 2 S100β associates with poor disease-free survival times in patients with endocrine-treated breast cancer. a S100β tissue expression strongly associated
with poor disease-free survival in a TMA patient cohort of 509 ERα-positive, endocrine-treated patients as determined by Kaplan-Meier estimates of disease-
free survival (HR 2.32, 95% CI is 1.58–3.40, p< 0.0001, Cox proportional hazard model). b 187 endocrine-treated ERα-positive patient serum samples were ana-
lyzed by ELISA for S100β using the established cut-off of 0.13 μg/L. S100β serum levels significantly associated with poor disease-free survival in the endocrine
therapy-treated patient population (HR 3.09, 95% CI is 1.66–9.68, p=0.002, Cox proportional hazard model). c Pre-operative elevated serum S100β returned to
normal following surgical resection of the tumor in matched patient blood samples as measured by ELISA (55 individual patients, 6 pre-operative S100β
≥0.13 and 49 pre-operative S100β <0.13, paired t test error bars refer to 95% CI, p= 0.023)
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Fig. 3 Metastasis forms in resistant breast cancer in vivo which is marked by S100β. a Endocrine sensitive MCF-7 and endocrine resistant LY2
cells were injected into the mammary fat pad of 6-week-old Balbc/SCID mice. Mice were treated with estrogen and with or without slow release
tamoxifen pellets. Tumor volume was decreased significantly in the endocrine sensitive model with tamoxifen treatment (p = 0.0005, n = 3), and
there was a small, but not significant, increase in tumor volume in the endocrine resistant model with tamoxifen treatment compared to the
untreated endocrine resistant model (p = 0.068, n = 3). There was also a significant increase in tumor volume with tamoxifen treatment in the
endocrine sensitive compared to endocrine resistant model (p = 0.0004, n = 3). b Metastasis was formed in the presence of tamoxifen treatment
at week 2 which increased gradually until the experimental endpoint. Metastasis was visualized and quantified using in vivo and ex vivo IVIS
imaging at the experimental endpoint (week 7). c Formation of metastasis in the organs was confirmed at experimental endpoint (week 7) by
immunohistochemical (IHC) analysis. Representative images of primary tissue, lung, liver, and bone. H&E staining demonstrated the presence
of tumor epithelial cells in the metastatic sites, and nuclear Ki67 indicated active proliferation. ERα expression was maintained throughout the
experiment in the primary tumor and in the lungs, liver, and bone metastases and S100β expression in primary tissue, lung, liver, and bone.
(Representative image n = 7.) d S100β levels in the serum of mice treated with tamoxifen increased concurrently with metastasis (non-parametric
t test of blood between weeks 5 and 7, p = 0.0012). e In matched patients who recurred on endocrine therapy high expression of S100β in their
primary tumor was maintained in metastatic tissue, while patients with low S100β in their primary tumor gained expression of S100β in their
metastatic tissue at diagnosis as determined by IHC analysis (n = 4). f Post-operative monitoring levels of S100β was significantly higher in patients
with metastatic disease (n = 96 Recurrence-Free and n = 22 Recurrence patients; error bars refer to 95% CI, p = 0.003)
Charmsaz et al. BMC Medicine  (2017) 15:79 Page 6 of 12
in sera was also found to significantly predict disease-free
survival on endocrine therapy (n = 187, HR 4.009, 95% CI
is 1.66–9.68, p = 0.002, Cox proportional hazard model)
(Fig. 2b, Table 1). S100β serum levels did not associate
with any clinicopathological parameters with the excep-
tion of the progesterone receptor (PR). The S100β assay
predicted disease recurrence in endocrine-treated patients
with a specificity of 93% and a sensitivity of 27%.
Matched pre-operative and post-operative (<12 months)
serum levels were measured in 55 patients. Surgical resec-
tion of the patient primary tumor returned elevated levels
of serum S100β to normal (6 individual patients with ele-
vated S100β, p = 0.023) (Fig. 2c, Additional file 2: Table S2).
These data suggest that elevated levels of S100β can mark
the presence of tumor burden in breast cancer patients
and have the potential to predict disease progression in a
subset of patients on endocrine treatment.
Metastasis forms in the presence of tamoxifen in resistant
breast cancer in vivo which is marked by S100β
Here we investigated alterations in tumor burden in endo-
crine sensitive versus resistant tumors in the presence and ab-
sence of treatment in an in vivo xenograft model. Tamoxifen-
treated endocrine resistant models had a greater tumor vol-
ume in comparison to tamoxifen-treated endocrine sensitive
models (p= 0.0004). A small increase in tumor volume was
observed in the tamoxifen-treated endocrine resistant xeno-
grafts in comparison to the untreated endocrine resistant
xenograft, though this was not significant (p= 0.0668) (Fig. 3a).
The development of metastatic disease was observed in
tamoxifen-treated endocrine resistant xenografts, and
formations of micrometastatic deposits in the lung,
liver, and bone were evident (Fig. 3b). Immunohisto-
chemical (IHC) analysis of the primary and the
matched metastatic tumors from the tamoxifen-
treated endocrine resistant xenografts showed expres-
sion of ER, as well as the proliferation marker Ki67,
in both the primary and metastatic tumors (Fig. 3c).
As we have previously reported, S100β is an output of a
network activated by prolonged exposure to endocrine
treatment [3]; therefore, it has the potential to act as a bio-
marker for the emergence of metastatic disease. Elevated
S100β serum levels at week 7 post-implantation coincided
with increased tumor burden and manifestation of distant
micrometastasis (two-sided Student’s t test, p = 0.0012)
(Fig. 3d). These observations were confirmed at the level of
the tumor tissue where expression of S100β, though un-
detectable in the lung, was highly expressed in the liver
and bone (Fig. 3c).
Elevated S100β protein during the treatment period
marks disease recurrence in endocrine-treated patients
In matched primary and metastatic tumors from patients
who had recurred on endocrine therapy (n= 4), S100β was
detected in all of the metastatic tumors even if it was absent
from the primary tumor tissue (Fig. 3e and Additional file 2:
Table S3).
In sequential serum samples taken during the treatment
period, elevated levels of S100β were recorded in endocrine-
treated patients with subsequent clinical and pathological
disease progression (n= 118, p= 0.003) (Fig. 3f and Table 2).
The S100β monitoring assay detected disease recurrence in
endocrine-treated patients with a specificity of 95% and a
sensitivity of 23%.
Patients with a positive S100β status who failed endo-
crine treatment had an enhanced risk of developing dis-
tant metastasis (79%) relative to local disease recurrence
(21%). Sites of distant recurrence recorded included the
bone, lung, and liver (Additional file 1: Figure S2).
Endocrine treatment can induce transcriptional regulation
of S100β which is disrupted by tyrosine kinase inhibition
We used cell line models to investigate the mechanism
of production of S100β in endocrine resistance. Elevated
levels of ERα, HOXC11, and SRC-1 along with their
Table 2 Associations of clinicopathologic variables and disease
outcome in ER-positive endocrine-treated breast cancer patients
(n= 118) with S100β using Fisher’s exact test. Median age was 51.22
years , median follow-up time was 59.71 months and monitoring blood
tests were taken >12 months post-operation (median 24.32 months)
S100β ≥0.13 μg/L
n = 10 (8.47%)
S100β <0.13 μg/L
n = 108 (91.53%)
p value
Age
≥55 3 (30%) 64 (59.26%) 0.099
< 55 7 (70%) 44 (40.74%)
PR
+ ve 8 (80%) 87 (80.56%) 1.00
–ve 2 (20%) 21 (19.44%)
HER2
+ ve 3 (30%) 52 (51.49%) 0.097
–ve 7 (70%) 49 (48.51%)
Node
+ ve 2 (22.22%) 43 (47.25%) 0.162
–ve 7 (77.78%) 48 (52.75%)
Grade
≥3 4 (40%) 26 (24.07%) 0.273
<3 6 (60%) 82 (75.93%)
Size
≥20 mm 7 (100%) 81 (96.43%) 1.00
< 20 mm – 3 (3.57%)
Recurrence
+ ve 5 (50%) 17 (15.74%) 0.019
(r = +0.245)
–ve 5 (50%) 91 (84.26%)
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transcriptional target S100β were observed in both tam-
oxifen resistant (LY2) and aromatase inhibitor (AI) re-
sistant (LetR) cells; however, no alteration was observed
in PR levels (Fig. 4a). Consistent with the enhanced
growth factor crosstalk described in endocrine resist-
ance, increased levels of p-AKT, p-ERK and in particular
p-Src were also observed in endocrine resistant cells
(Fig. 4a, Additional file 1: Figure S3A).
Elevated levels of p-Src driven by endocrine treatment
and growth factors were reduced by the specific p-Src in-
hibitor PP2 and the Src-ABL inhibitor dasatinib (Add-
itional file 1: Figure S3B). Treatment driven HOXC11
interactions with its coactivator SRC-1 and HOXC11/
SRC-1 recruitment to the S100β promoter were disrupted
by p-Src kinase inhibition (Fig. 4b, Additional file 1: Figure
S3C). Furthermore, tamoxifen-induced transcript and pro-
tein levels of S100β were inhibited in the presence of PP2
and dasatinib in the treatment resistant LY2 cells (Fig. 4c,
Additional file 1: Figure S3D). Taken together, these mo-
lecular studies provided us with a model of S100β produc-
tion in endocrine resistant breast cancer where endocrine
treatment can induce rapid tyrosine kinase signaling to in-
duce HOXC11/SRC-1 transcriptional activation of S100β.
This signaling network can be disrupted in the presence
of the p-Src kinase inhibitors PP2 or dasatinib (Additional
file 1: Figure S3D).
Tyrosine kinase signaling inhibition can repress the
production of S100β and impede tumor progression in
endocrine resistant breast cancer
Functionally, inhibition of p-Src with dasatinib alone
and in combination with endocrine therapy reduced cell
proliferation in tamoxifen and AI resistant breast cancer
cells (Additional file 1: Figure S4A). In endocrine resist-
ant xenografts treated with tamoxifen, the addition of
dasatinib therapy significantly reduced tumor volume in
comparison to tamoxifen alone (two-sided Student’s t
test, p < 0.05, Fig. 5a). Moreover, treatment with dasati-
nib increased cellular differentiation of the primary
tumor and, in line with our in vitro proliferation studies,
significantly reduced Ki67 expression (two-sided Stu-
dent’s t test, p < 0.01, Additional file 1: Figure S4B).
In vivo p-Src inhibition reduced the endocrine-regulated
signaling network. Dasatinib-treated mice maintained
ERα status and reduced primary tumor expression of
p-Src kinase, the co-activator SRC-1, the transcription
factor HOXC11, and their target gene S100β (Fig. 5b,
Additional file 1: Figure S5).
The ability of p-Src inhibition to affect endocrine
therapy-induced metastatic progression was investigated.
In cell line models of endocrine resistance and metastatic
disease, dasatinib significantly reduced cell migration
(Additional file 1: Figure S6A). Confirming a role for the
Fig. 4 Endocrine treatment induces transcriptional regulation of S100β which is disrupted by tyrosine kinase inhibition. a Expression of ERα, PR, p-Src, c-Src,
HOXC11, SRC-1, S100β, and β-actin in a panel of endocrine resistant (LY2, LetR) and sensitive (MCF-7, ARO) cell lines (representative blots from n= 3). b Chroma-
tin immunoprecipitation of SRC-1 and HOXC11 of the S100β promoter region in LY2 cells treated with tamoxifen alone or in combination with dasatinib in-
hibits SRC-1 and HOXC11 recruitment to the S100β promoter (graphs are representative of the mean relative recruitment values relative to tamoxifen-treated
controls, n=3± SEM, p≤ 0.05). c Inhibition of S100β protein expression with tyrosine kinase inhibitors PP2 or dasatinib in the endocrine resistant LY2 cells
treated with tamoxifen (representative blots from n=3). d Schematic representation of S100β pathway, showing long-term exposure to endocrine therapy in-
duces expression of S100β in an Src-dependent manner
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adaptive signaling network in the migratory process,
forced expression of the S100β transcriptional machinery
(SRC-1 and HOXC11) significantly induced migration in
endocrine sensitive cells, which was abolished with dasati-
nib treatment (Additional file 1: Figure S6B and C).
Consistent with the ability of S100β to mark the exist-
ence of disease progression in our patient population and
in our xenograft model, treatment with dasatinib reduced
circulating S100β levels in the xenografts compared to
endocrine treatment alone (Fig. 5c). Furthermore, in
breast cancer patients with clinically confirmed disease re-
currence on AI therapy, ex vivo treatment of the resistant
tumors with dasatinib in combination with letrozole
maintained ERα expression, reduced Ki67, and switched
off S100β expression in comparison to letrozole treatment
alone (n = 2) (Fig. 5d and Additional file 2: Table S4). To-
gether these data establish S100β as an output of the
endocrine resistance network and support its use as a
serum marker of the emergence of endocrine-related
metastatic disease in breast cancer patients.
Discussion
Early diagnosis of treatment resistant metastatic tumors
will have a significant impact on the management of ER-
positive patients who have failed endocrine treatment.
To date gene signature assays of the primary tumor,
such as EndoPredict and the PAM50 assay, can inform
adjuvant treatment strategies [27–29]. However, these
prognostic assays may have limited capability to take
into consideration the ability of the tumor to adapt to its
therapeutic environment or to monitor real-time patient
treatment response.
The importance of tumor molecular heterogeneity in
determining response to targeted therapy is now firmly
established [30]. Furthermore, the ability of a subset of
breast tumors to alter their molecular profile between pri-
mary and recurrent tumors is the subject of intense inves-
tigation [26, 31]. This tumor adaptability is controlled, at
least in part, through transcription factors including HOX
family members responding to the therapeutic environ-
ment [3, 32, 33].
Here we describe a mechanistically based serum bio-
marker, S100β, which is an output of an adaptability sig-
naling network known to be important in the
development of endocrine resistance [3]. Both tissue and
serum S100β protein can predict disease-free survival in
ER-positive endocrine-treated patients. No association
was observed between either tissue or serum S100β and
classic clinicopathological parameters, with the exception
of a strong association between S100β serum and PR,
Fig. 5 Combined endocrine and Src-kinase inhibitor treatment decreases tumor burden, which is marked by reduction in S100β. a In vivo model of endocrine resist-
ant xenograft treated with dasatinib (50 mg/kg/day) in combination with tamoxifen showed a significant inhibition of tumor growth (mean tumor volume from caliper
measurement, n=7, error bars refer to 95% CI, p<0.05). Representative IVIS images of mice at week 1 and week 7. Representative IVIS ex vivo images of tumor metas-
tasis to lung, liver, and bone. b IHC analysis of tamoxifen-treated primary tumor from the endocrine resistant xenograft showed ERα expression and inhibition of Ki67,
p-Src, SRC-1, HOXC11, and S100β expression after treatment with dasatinib. c Serum levels of S100β reduced in the xenograft mice treated with dasatinib at week 7
(n=5, p=0.085 one-tailed t test). d IHC revealed that dasatinib decreased expression of S100β and the proliferative marker Ki67 while maintaining the expression of
ERα in an ex vivo explant model of tumor tissue from endocrine resistant patients after treatment with letrozole in the presence or absence of dasatinib (n=2)
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which is consistent with the proposed role for PR and en-
hanced kinase signaling [34].
The ELISA-based S100β assay has a sensitivity of 27%,
which is reflective of its ability to identify a subset of pa-
tients who subsequently have disease relapse. However,
the specificity of the assay is high at 93%, indicating that
the assay is accurate. The clinical value of this assay is
that it can successfully detect patients who will not re-
lapse [35]. Moreover, in this study monitoring S100β
serum levels during the treatment period identified pa-
tients with subsequent clinical and pathological disease
recurrence with a specificity of 95% and a sensitivity of
23%. These serum studies are somewhat limited due to
the relatively low number of patients, which reflects the
challenges in collecting serial serum samples from
endocrine-treated breast cancer patients. The data pre-
sented in this study suggest that a large multicenter clin-
ical trial to evaluate the efficacy of serum S100β for
routine surveillance of ER-positive patients during their
endocrine treatment period is now warranted.
Known growth factor/endocrine signaling crosstalk in re-
sistant breast cancer makes targeting kinase pathways an
attractive management strategy [13]. The data presented in
this study suggest that a select number of endocrine resist-
ant patients would benefit from kinase inhibition. In endo-
crine resistant cell lines and in vivo models, endocrine
treatment activated kinase-dependent adaptability signaling
networks and drove tumor cell growth and migration. In-
hibition of kinase signaling with the pan-Src-ABL inhibitor
dasatinib turned off the adaptability network, restored
endocrine sensitivity, and retarded disease progression. Of
note, reduced tumor aggression was marked by a decrease
in S100β protein in both in vivo endocrine resistant models
and in ex vivo tumors from patients with endocrine resist-
ant breast cancer. Therefore, breast cancer patients with el-
evated S100β may benefit from combined endocrine and
kinase inhibitor treatment.
Conclusions
In conclusion, identification of the adaptability network with
S100β has the potential to provide new information regard-
ing the response of the patient tumor to ongoing endocrine
therapy and act as a companion diagnostic to increase the
efficacy of combined tyrosine kinase inhibitor treatment.
Additional files
Additional file 1: Figure S1. Training set to establish S100β elevated
cut-off. Serum S100β levels were determined using a commercial ELISA
kit (Diasorin) according to the manufacturer’s instructions. To determine
an appropriate S100β cut-off level, a training set was constructed
comprising ten breast cancer patients with no relapse (No Recurrence),
ten patients who went on to have confirmed disease recurrence
(Recurrence), and ten aged matched controls (Normal). The upper limit of
normal was calculated (mean + (t0.975,n-1 x √(n+1/n) x SD)), 0.13 μg/L was
considered the upper end of normal and was taken as the cut-off. Patient
clinicopathological parameters and treatment details are provided for No
Recurrence and Recurrence patients. Median age of control patients is
62.8 years. Figure S2. Site of recurrence in patients with elevated S100β.
Site of recurrence in patients with elevated pre-operative or monitoring
serum S100β levels (n = 13). Figure S3. Dasatinib successfully inhibits
p-Src expression in endocrine resistant breast cancer. (A) Expression of
p-AKT, AKT, P-ERK, and ERK in panel of endocrine resistant (LY2, LetR) and
sensitive (MCF-7, ARO) cell lines. (B) Tamoxifen resistant cells LY2 expressed
increased levels of p-Src when treated with tamoxifen which was inhibited
with PP2 (10 μM) and dasatinib (0.1 μM). Letrozole resistant cells LetR
expressed increased levels of p-Src when treated with EGF which was
inhibited with PP2 (10 μM) and dasatinib (0.1 μM). (C) Interactions between
SRC-1 and the transcription factor HOXC11 were increased by 4-OHT
(1 × 10–7 M) in tamoxifen resistant LY2 cells and by EGF (10 ng/ml) in
letrozole resistant LetR cells. These interactions were inhibited in both cell
lines by pre-treatment with the p-SRC inhibitors PP2 (10 μM) and dasatinib
(0.1 μM). (D) mRNA expression of the HOXC11/SRC-1 complex’s downstream
target gene S100β increased with tamoxifen (T) treatment compared with
vehicle (V). This tamoxifen-induced expression was successfully inhibited
when treated with dasatinib (D). Figure S4. Proliferation in resistant breast
cancer cell lines following dasatinib treatment. (A) Dasatinib treatment
(1 μM) for 72 h inhibits both estrogen- and tamoxifen-driven proliferation
of the tamoxifen resistant cell line LY2 and AI resistant LetR measured by
MTS assay (n = 3). (B) Expression of nuclear Ki67 significantly decreased in
the dasatinib-treated xenograft primary tumors (p = 0.01). Studying the
architecture of the epithelial cells in the primary tumors by H&E staining
revealed that dasatinib-treated tumors had a more organized cell
population than that of the controls. Figure S5. SRC-1 and HOXC11
scoring of primary tumors from endocrine resistant xenograft model.
Primary tumors from vehicle- and dasatinib-treated mice were stained
for SRC-1 and HOXC11 and analyzed for total positivity using Aperio
Imagescope software. Results are expressed as mean protein positivity ±
SEM, p≤ 0.05. The expression of SRC-1 and HOXC11 was decreased in the
dasatinib-treated group compared to that of the vehicle-treated group.
Figure S6. Migratory potential which can be inhibited by dasatinib. (A)
The migratory potential of endocrine resistant cell lines (LY2 and LetR) is
elevated in comparison to that of their parental, the non-migratory cell line
MCF-7. This migration was comparable to that of the highly metastatic triple
negative breast cancer cell line MDA-MB-231. Treatment with dasatinib
significantly inhibited this migration (p < 0.05). (B) Endocrine sensitive MCF-7
cells were stably transfected with SRC-1 and HOXC11 vectors to assay
the effects of these proteins on migratory potential. The successful
overexpression was confirmed by western blot (n = 3). (C) Overexpression
of the transcription factor HOXC11 and SRC-1 significantly increased the
migration of MCF-7 compared to the empty vector transfected cells (p< 0.05).
Dasatinib treatment (1 μM) significantly inhibited both HOXC11- and SRC-1-
driven cellular migration (p< 0.001). (PPTX 670 kb)
Additional file 2: Table S1. (A) S100β validation set (n = 76 ER-positive
and ER-negative patients). (B) S100β validation set (n = 59 ER-positive
patients). Association of S100β status with clinicopathological variables
and disease recurrence using Fisher’s exact test. Table S2. Pre-operative and
post-operative S100β serum levels in 55 ER-positive patients. Association of
S100β status with clinicopathological variables using Fisher’s exact test.
Table S3. S100β tissue expression in matched primary and metastatic tissue
from ER-positive patients. Table S4. Patient details from explant study.
Explant endocrine resistant tumor tissue (n = 2) was treated with AI therapy
(letrozole) in the presence and absence of dasatinib. (PPTX 93 kb)
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